Optimizing number of cycles of induction chemotherapy for patients with nasopharyngeal carcinoma: Retrospective survival analysis
Optimizing number of cycles of induction chemotherapy for patients with nasopharyngeal carcinoma: Retrospective survival analysis
复制标题
优化鼻咽癌诱导化疗周期数：回顾性生存分析
DOI：
10.1002/hed.26141
复制
发表时间：
2020-08-01
影响因子：
2.9
通讯作者：
Peng, Xingchen
中科院分区：
文献类型：
--
作者：
He, Yan;Zhao, Zhihao;Peng, Xingchen
背景 诱导化疗后同步放化疗是鼻咽癌患者的护理标准之一，但最佳诱导周期数尚不清楚。在这里，我们比较了接受 2 至 4 个周期治疗的患者的生存数据。方法对2009年1月至2015年12月四川大学华西医院收治的鼻咽癌患者进行回顾性分析。结果 673 名患者符合资格标准。中位随访 53 个月（四分位数范围，38-74）后，2 个周期和 3 个周期的总生存率没有差异（88.14% vs 91.24%）。但四个周期与较差的总生存率（79.12%）和较高的治疗相关毒性发生率相关。多变量分析显示诱导周期数和淋巴结分类是预后因素。结论 两个和三个周期的诱导化疗与相似的生存率相关，而四个周期会降低流行地区的生存率并增加治疗相关的毒性。
Background Induction chemotherapy followed by concurrent chemoradiotherapy is one of the standards of care for patients with nasopharyngeal carcinoma, but the optimal number of induction cycles is unclear. Here we compared survival data from patients treated with 2 to 4 cycles. Methods Patients with nasopharyngeal carcinoma at West China Hospital of Sichuan University between January 2009 and December 2015 were retrospectively analyzed. Results Six hundred and seventy three patients met eligibility criteria. After a median follow-up of 53 months (interquartile range, 38-74), there was no difference between 2 and 3 cycles in overall survival (88.14% vs 91.24%). But four cycles were associated with worse overall survival (79.12%) and higher incidence of treatment-related toxicities. Multivariate analysis showed that the number of induction cycles and lymph node classification were prognostic factors. Conclusions Two and three cycles of induction chemotherapy are associated with similar survival, while four cycles reduce survival and increase treatment-related toxicity in endemic regions.